EO2002

About Emmecell

Emmecell is a San Diego-based biotech developing regenerative cell therapies for ocular diseases using its proprietary Magnetic Cell Delivery (MCD) platform. This technology uses magnetic nanoparticles to guide and hold therapeutic cells at the target site, aiming to improve efficacy over traditional cell delivery methods. The company's lead candidate, EO2002, is a first-in-class, non-surgical cell injection for corneal edema, positioning it to address a major unmet need in corneal transplantation. Emmecell also operates a subsidiary, CellMP, which provides cGMP manufacturing services for cell therapies to other biotech companies.

Therapeutic Areas